This retrospective study reviewed 922 consecutive patients with Ad-HCC who received combined therapy at three hospitals from April 1, 2019, to October 31, 2022. The inclusion criteria were as follows: (1) The patients in the C-A group all met the following requirements: (1) at least one time camrelizumab injection;
(2) at least 1 month apatinib treatment; (3) the injection of camrelizumab occurred the administration of apatinib; (4) during the apatinib plus camrelizumab treatment without any local treatments including ablation, TACE and HAIC. By contrast, the patients included in the TRIPLET group met the following criteria: (1) at least one time camrelizumab injection; (2) at least 1 month apatinib treatment; (3) at least 1 HAIC circle; (4) the injection of camrelizumab occurred during the administration of apatinib; (5) HAIC was performed during or in the previous week to the administration of apatinib; (6) (link) during the apatinib plus camrelizumab treatment without any local treatments including ablation and TACE. All participating institutions strictly followed the inclusion and exclusion criteria to ensure consistency in the baseline characteristics of the population. The treatment regimen for patients would be recommended by the multi-disciplinary team (MDT) that consist of surgical oncologists, radiotherapist, diagnostic radiologist and interventional radiologist. Final decision-making was dominated together with patients and their family members according to patients' willingness and economic condition.
(2) at least 1 month apatinib treatment; (3) the injection of camrelizumab occurred the administration of apatinib; (4) during the apatinib plus camrelizumab treatment without any local treatments including ablation, TACE and HAIC. By contrast, the patients included in the TRIPLET group met the following criteria: (1) at least one time camrelizumab injection; (2) at least 1 month apatinib treatment; (3) at least 1 HAIC circle; (4) the injection of camrelizumab occurred during the administration of apatinib; (5) HAIC was performed during or in the previous week to the administration of apatinib; (6) (link) during the apatinib plus camrelizumab treatment without any local treatments including ablation and TACE. All participating institutions strictly followed the inclusion and exclusion criteria to ensure consistency in the baseline characteristics of the population. The treatment regimen for patients would be recommended by the multi-disciplinary team (MDT) that consist of surgical oncologists, radiotherapist, diagnostic radiologist and interventional radiologist. Final decision-making was dominated together with patients and their family members according to patients' willingness and economic condition.
